A global quality and innovation-led CDMO in cell and gene therapy

Delivering end-to-end CDMO solutions at clinical and commercial scale


OXB

At a glance

Bringing a cell and gene therapy to market is a complex journey. It demands navigation through intricate development and manufacturing processes, alongside a dynamic and evolving regulatory landscape. Scaling production adds further challenges – slowing innovation, delaying time-to-clinic, and increasing costs. Without the right expertise and infrastructure, these barriers can prevent life-changing therapies from reaching the patients who need them most.

That's where OXB makes the difference. As a global leader in viral vector development, OXB offers world-class capabilities across AAV, lentiviral, and other vector types. With over 30 years of experience in vector design, process optimisation, and scale-up, we help our clients overcome complexity and accelerate progress from early development to commercial launch.

Our state-of-the-art, scalable manufacturing facilities – strategically located in key biotech hubs - enable global reach and flexible production. Backed by a strong track record of successful collaborations and highly experienced technical and delivery teams, OXB is the trusted partner to bring advanced therapies to life, faster.

"The collaboration has always been easy and personalized. There have been hurdles but we have overcome them together."

Client satisfaction survey, 2025

A global quality and innovation-led CDMO

OXB is a global, full-service, quality and innovation-led viral vector CDMO with deep expertise in the development, scale-up, and GMP manufacture of cell and gene therapy products. With over 30 years of experience, we are a trusted partner to leading biopharma companies, offering a variety of CDMO solutions ranging from proprietary platforms, fully customised solutions and tech transfer, across the viral vector lifecycle.

Our success is based on your success

We develop technical solutions that address industry challenges

We offer high-quality services backed by our proven regulatory track record

We build partnerships to ensure your success

Flexible delivery models for our clients

We offer a range of collaboration models designed to meet you where you are in your gene therapy journey. Whether you're looking to leverage our platforms, tailor a custom solution, or transfer in your existing process into our GMP facilities, our deep expertise spans the entire development journey.

Platform project:

For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process

Custom solution:

For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate

Technology transfer:

For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale-up and/or long-term manufacture

Proven expertise and best-in-class capabilities

Our capabilities



Our experience



An unmatched 30-year track record in viral vector manufacturing



Why choose OXB to develop and manufacture your life-changing therapy?

Unrivalled operational expertise, proven results

With over 30 years of experience and a track record across multiple vector types, OXB offers deep scientific and technical expertise to ensure efficient, high-quality manufacturing. Our operational excellence translates into cutting-edge solutions, seamless execution, and reliable outcomes for our clients.

Beyond a service provider: a strategic partner for your success

At OXB, we don't just manufacture, we collaborate. We take a consultative, phase-appropriate approach, proactively working with you to understand your objectives, navigate constraints, and find the best path forward. Our agility and expertise enable us to de-risk development and accelerate progress at every stage. We foster a culture of flexibility to meet our clients' goals with tailored solutions.

Investing in innovation to shape the future of cell & gene therapy

The cell and gene therapy landscape is evolving rapidly – and so are we. OXB is committed to advancing the field through ongoing investment in innovation, including proprietary technologies that enhance efficiency, potency, and scalability. By pushing the boundaries of what's possible, we empower our clients to deliver next-generation therapies to patients faster.

Global footprint for greater flexibility

State-of-the-art facilities with platform technologies delivered from all 3 geographies



We have been inspected and approved by:

- FDA
- MHRA
- EMA
- Anvisa
- PMDA
- MFDS

With our global network, we cover the entire value chain of our clients' vector, from development to release.

Located in the UK, USA and Europe

With operations across the UK, US, and France, our manufacturing facilities are located in key biotech hubs close to our clients. Our state-of-the-art GMP facilities are equipped with the latest process development, analytics, and large-scale vector manufacturing technologies, ensuring rapid and reliable delivery of viral vectors for our clients. These credentials underscore our ability to consistently meet the highest quality and regulatory standards.

End-to-end CDMO services

OXB provides comprehensive CDMO services from early-stage development through to commercial supply, including:

- Process and analytical development for both suspension and adherent systems
- Tech transfer and scale-up into GMP-compliant manufacturing suites
- QC and release testing with a full suite of validated assays
- Automated fill-finish for clinical and commercial vector supply
- Regulatory support across global jurisdictions

OXB regulatory support

Whether you are targeting the US, Europe, China or other global markets, our end-to-end regulatory services ensure your product meets agency requirements to optimise market entry, faster and smarter. From strategy to maintenance, together, we execute a multi-disciplinary plan to expedite your product development founded on OXB science and technologies.

We deliver end to end regulatory support coupled with CMC manufacturing expertise, shaping early value propositions, guiding development through approval, engaging global regulators, and optimising post-approval portfolios to ensure compliant, efficient, and commercially focused pharmaceutical product lifecycles.

OXB analytical services

We offer an exceptionally comprehensive suite of assays, with 85% performed in house, ensuring full vector characterisation, quality control and stability testing, and preparing CMC modules for regulatory filings. We have an extensive clinical track record with our own and our clients' products, and can advise our clients in the selection of appropriate assays. We also develop custom-made assays for specific applications or types of product. **OXB is one of the very few companies in the world that can offer in-house, CGMP, RCL (Replication-competent lentiviruses) testing from purpose-built category 3 labs.** Our manufacturing sites are registered with the FDA, and we hold manufacturing authorisations for clinical trial products and commercial products.

Flexible development and manufacturing services

For all vector types at any clinical phase



Discover our unique LentiVector™ platform

Taking novel therapies from discovery to commercialisation

OXB's LentiVector™ platform offers a fully integrated and optimised suite of technologies and processes for the scalable production of high-quality lentiviral vectors. Designed to meet the complex demands of the cell and gene therapy market, the platform encompasses vector design, upstream and downstream processing, analytics, and fill/finish services, all aligned to deliver robust, reproducible GMP manufacturing.

The platform offers 3rd generation and 4th generation lentiviral vector systems (the TetraVecta™ system), including proprietary innovations; 2KO genome™, SupA-LTR™, MaxPax™, and the TRiP System™, that together can enhance vector potency, productivity, quality, and safety.

With the LentiVector™ platform, clients benefit from high-yield, high-volume GMP manufacturing, scalable from early preclinical to commercial supply, supported by deep regulatory expertise across global markets.

Access to unique technologies

TetraVecta™ system: After many years of research to improve the features of lentiviral vectors, OXB has launched this new lentiviral vector system to further improve the quality, potency and safety of lentiviral vectors, while increasing transgene packaging capacity.

LentiStable™ cell lines: OXB's cutting edge LentiStable™ technology platform allows the development of a mammalian cell line which can use a chemical inducer to generate viral vector production without the need for transient transfection. This technology has the potential to deliver highly efficient producer cell lines, enabling streamlined, scalable and cost-effective manufacturing.

OXB's lentiviral vector track record

- 390+ GMP batches released
- 9-12 months to GMP
- 1.9E+12 TU at 200L scale
- 85% analytical assays performed in-house

Discover our proven inAAVate™ platform

Accelerating AAV success from design to GMP

OXB's inAAVate™ platform provides a robust, standardised foundation to help clients achieve clinical and commercial milestones faster. Our end-to-end platform integrates proprietary technologies across construct design, upstream and downstream processing, analytics, and fill/finish. Clients can access the Triple Plasmid, or Dual Plasmid System, which together with our proprietary transfection process are responsible for increasing bioreactor vg titre up to 10-fold over typical industry standards.

By leveraging proprietary process innovations and analytical expertise, OXB enables faster GMP batch release and accelerated time to market.

With the inAAVate™ platform, clients can progress from project initiation to their first GMP batch in as little as 7 months.

Access to unique technologies

Dual-plasmid transfection system: Our team of experts at OXB have developed a proprietary 'plug and play' Dual-Plasmid system for transient transfection for effective AAV-based gene therapies resulting in higher titer, high product quality and proven scalability.

"After interacting with a number of CDMOs, OXB's AAV capabilities are truly the best in the industry."

Client satisfaction survey, 2025

OXB's AAV track record

- 50+ GMP batches released
- 7 – 9 months to GMP
- 1.5E+17vgs at 500L scale
- 90% typical full capsids in final product
- 90% analytical assays performed in-house

Seamless technology transfer: empowering your journey from concept to market

Give your therapy the launch it deserves

OXB's technology transfer service is designed to accelerate the commercialisation of transformative cell and gene therapies. Our structured, phase-appropriate approach ensures a seamless and efficient transfer of critical knowledge, technology, and processes, enabling rapid clinical and commercial success.

Leverage our proven track record in commercialisation

With over 30 years of experience in viral vector development, OXB has successfully delivered more than 50 successful initial clinical and commercial regulatory submissions. Our facilities have been inspected and approved by leading regulatory agencies, including the FDA, MHRA, EMA, ANVISA, PMDA, and MFDS. Clients partnering with OXB can trust in our extensive expertise to navigate the complexities of commercialisation with confidence.

Streamline the process with a tailored, phase-appropriate approach

Our technology transfer strategy is meticulously structured to align with each stage of development, eliminating unnecessary activities and optimising efficiency. This tailored approach ensures streamlined execution, reducing time to market without compromising quality or compliance.

Access our analytical know-how

A critical aspect of technology transfer is the ability to implement and interpret robust analytical methodologies. With a portfolio of over 40 in-house assays, our highly trained scientists possess the expertise to select the most appropriate analytical methods and identify meaningful deviations, ensuring process integrity and product quality.

Our tech transfer process

Key features of our tech transfer process:

- Full transparency with detailed project plans
- Dedicated project management and technical teams
- Fast-tracked process optimisation and scale-up
- Stringent quality control at every stage

Proposal Development

Gap Analysis

Process & Analytical Transfer

New Vector Introduction

GMP Batch Start-up

Your vision, our expertise
A partnership to transform lives

Mission
To enable our clients to deliver life-changing therapies to patients

Vision
To transform lives through cell and gene therapy

Strategy supported by a clear mission and vision

We are proud to deliver life-changing therapies together

Our values



Let’s deliver life-changing therapies together

OXB

To discuss your project, please contact our team at
partnering@oxb.com

www.oxb.com

Oxford Biomedica PLC,
Windrush Court,
Transport Way, Oxford,
OX4 6LT, United Kingdom